1
|
Val-Blasco A, Piedras MJGM, Ruiz-Hurtado G, Suarez N, Prieto P, Gonzalez-Ramos S, Gómez-Hurtado N, Delgado C, Pereira L, Benito G, Zaragoza C, Domenech N, Crespo-Leiro MG, Vasquez-Echeverri D, Nuñez G, Lopez-Collazo E, Boscá L, Fernández-Velasco M. Role of NOD1 in Heart Failure Progression via Regulation of Ca 2+ Handling. J Am Coll Cardiol 2017; 69:423-433. [PMID: 28126160 DOI: 10.1016/j.jacc.2016.10.073] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Revised: 10/05/2016] [Accepted: 10/25/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND Heart failure (HF) is a complex syndrome associated with a maladaptive innate immune system response that leads to deleterious cardiac remodeling. However, the underlying mechanisms of this syndrome are poorly understood. Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) is a newly recognized innate immune sensor involved in cardiovascular diseases. OBJECTIVES This study evaluated the role of NOD1 in HF progression. METHODS NOD1 was examined in human failing myocardium and in a post-myocardial infarction (PMI) HF model evaluated in wild-type (wt-PMI) and Nod1-/- mice (Nod1-/--PMI). RESULTS The NOD1 pathway was up-regulated in human and murine failing myocardia. Compared with wt-PMI, hearts from Nod1-/--PMI mice had better cardiac function and attenuated structural remodeling. Ameliorated cardiac function in Nod1-/--PMI mice was associated with prevention of Ca2+ dynamic impairment linked to HF, including smaller and longer intracellular Ca2+ concentration transients and a lesser sarcoplasmic reticulum Ca2+ load due to a down-regulation of the sarcoplasmic reticulum Ca2+-adenosine triphosphatase pump and by augmented levels of the Na+/Ca2+ exchanger. Increased diastolic Ca2+ release in wt-PMI cardiomyocytes was related to hyperphosphorylation of ryanodine receptors, which was blunted in Nod1-/--PMI cardiomyocytes. Pharmacological blockade of NOD1 also prevented Ca2+ mishandling in wt-PMI mice. Nod1-/--PMI mice showed significantly fewer ventricular arrhythmias and lower mortality after isoproterenol administration. These effects were associated with lower aberrant systolic Ca2+ release and with a prevention of the hyperphosphorylation of ryanodine receptors under isoproterenol administration in Nod1-/--PMI mice. CONCLUSIONS NOD1 modulated intracellular Ca2+ mishandling in HF, emerging as a new target for HF therapy.
Collapse
Affiliation(s)
- Almudena Val-Blasco
- Innate Immune Response Group, Instituto de Investigación La Paz, La Paz University Hospital, Madrid, Spain
| | - María Jose G M Piedras
- Department of Cardiology, University Hospital Ramón y Cajal/University Francisco de Vitoria, Madrid, Spain
| | - Gema Ruiz-Hurtado
- Unidad de Hipertensión, Instituto de Investigación i+12 Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Natalia Suarez
- Cardiology Department, Instituto de Investigación Biomédica de A Coruña, Complexo Hospitalario Universitario de A Coruña, Servicio Gallego de Salud, Universidade da Coruña, Coruña, Spain
| | - Patricia Prieto
- Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Silvia Gonzalez-Ramos
- Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Nieves Gómez-Hurtado
- Departament of Pharmacology, School of Medicine, Complutense University, Madrid, Spain
| | - Carmen Delgado
- Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas, Madrid, Spain; Departament of Pharmacology, School of Medicine, Complutense University, Madrid, Spain
| | - Laetitia Pereira
- Department of Pharmacology, University of California, Davis, Davis, California
| | - Gemma Benito
- Innate Immune Response Group, Instituto de Investigación La Paz, La Paz University Hospital, Madrid, Spain
| | - Carlos Zaragoza
- Department of Cardiology, University Hospital Ramón y Cajal/University Francisco de Vitoria, Madrid, Spain
| | - Nieves Domenech
- Biobanco A Coruña, Complexo Hospitalario Universitario A Coruña e Instituto de Investigación Biomédica, Coruña, Spain
| | - María Generosa Crespo-Leiro
- Cardiology Department, Instituto de Investigación Biomédica de A Coruña, Complexo Hospitalario Universitario de A Coruña, Servicio Gallego de Salud, Universidade da Coruña, Coruña, Spain
| | - Daniel Vasquez-Echeverri
- Cardiology Department, Instituto de Investigación Biomédica de A Coruña, Complexo Hospitalario Universitario de A Coruña, Servicio Gallego de Salud, Universidade da Coruña, Coruña, Spain
| | - Gabriel Nuñez
- Department of Pathology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan
| | - Eduardo Lopez-Collazo
- Innate Immune Response Group, Instituto de Investigación La Paz, La Paz University Hospital, Madrid, Spain; Center for Biomedical Research Network, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain
| | - Lisardo Boscá
- Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
| | - María Fernández-Velasco
- Innate Immune Response Group, Instituto de Investigación La Paz, La Paz University Hospital, Madrid, Spain.
| |
Collapse
|